Price: $308.8800
$3.98
1.305%
|
Day's High:
| $311.28
| Week Perf:
| 2.89 %
|
Day's Low: |
$ 303.69 |
30 Day Perf: |
-1.63 % |
Volume (M): |
1,232 |
52 Wk High: |
$ 319.74 |
Volume (M$): |
$ 380,633 |
52 Wk Avg: |
$262.01 |
Open: |
$310.69 |
52 Wk Low: |
$188.54 |
|
|
Market Capitalization (Millions $) |
44,849 |
Shares
Outstanding (Millions) |
145 |
Employees |
9,610 |
Revenues (TTM) (Millions $) |
10,105 |
Net Income (TTM) (Millions $) |
3,131 |
Cash Flow (TTM) (Millions $) |
-541 |
Capital Exp. (TTM) (Millions $) |
227 |
Biogen Inc
Biogen Idec creates new standards of care in oncology and immunology. As a global
leader in the development, manufacturing, and commercialization of novel therapies,
we transform scientific discoveries into advances in human healthcare. We currently
have four commercial products: AVONEX' (Interferon beta-1a) for the treatment
of relapsing multiple sclerosis, also known as MS, RITUXAN' (rituximab)'and ZEVALIN'
(ibritumomab tiuxetan), both of which treat certain B-cell non-Hodgkin's lymphomas,
also referred to as B-cell NHLs, and AMEVIVE' (alefacept)'for the treatment of
adult patients with moderate-to-severe chronic plaque psoriasis who are candidates
for systemic therapy or phototherapy.
Our sales and marketing efforts are generally focused on specialist physicians
in private practice or at major medical centers. We utilize common pharmaceutical
company practices to market our products and to educate physicians, including
sales representatives calling on individual physicians and distributors, advertisements,
professional symposia, direct mail, selling initiatives, public relations and
other methods. We have also established uninsured patient programs in the U.S.'
for our marketed products which provide qualified patients with products at
no charge. We also provide certain customer service and other related programs
for our products, such as disease and product-specific websites, insurance verification
services and order, delivery and fulfillment services.
Competition in the biotechnology and pharmaceutical industries is intense and
comes from many and varied sources. We do not believe that any of the industry
leaders can be considered dominant in view of the rapid technological change
in the industry. We experience significant competition from specialized biotechnology
firms in the U.S., the EU and elsewhere and from many large pharmaceutical,
chemical and other companies.
AVONEX
AVONEX competed in the U.S. and EU markets primarily with three products:
''BETASERON', sold by Berlex in the U.S. and sold under the name BETAFERON'
by Schering A.G.
''REBIF', which is co-promoted by Serono, Inc. and Pfizer in the U.S. and sold
by Serono AG in the EU.
''COPAXONE' glatiramer acetate, sold by Teva Neuroscience, Inc. in the U.S.
and co-promoted by Teva and Aventis Pharma in the EU.
RITUXAN is typically used after patients fail to respond or relapse after treatment
with traditional radiation therapy or standard chemotherapy regimes, such as
CVP and CHOP. ZEVALIN is typically used after patients fail to respond or relapse
following treatment with RITUXAN. ZEVALIN competes with BEXXAR' (tositumomab,
iodine I-131 tositumomab), a radiolabeled molecule developed by Corixa Corporation
and GlaxoSmithKline. BEXXAR received FDA approval in June 2003 to treat patients
with CD20+, follicular, NHL, with and without transformation, whose disease
is refractory to RITUXAN and has relapsed following chemotherapy.
AMEVIVE
AMEVIVE competes with several different types of therapies including:
''traditional therapies for moderate-to-severe chronic plaque psoriasis, such
as oral retinoids, steroids, methotrexate, cyclosporin, PUVA and UVB radiation.
''RAPTIVA' (efalizumab), a drug co-developed by Genentech and Xoma Corporation
that was approved by the FDA in November 2003 to treat moderate-to-severe psoriasis.
Serono has an exclusive license to RAPTIVA in the EU and other countries and
has filed for regulatory approval of the drug in the EU. Drugs approved for
other indications that are used to treat psoriasis. Among these drugs are ENBREL'
(etanercept), REMICADE' (infliximab)'and HUMIRA'(adalimumab). ENBREL is sold
by Amgen, Inc. and Wyeth Pharmaceuticals, Inc. and is approved to treat psoriatic
arthritis. In January 2003, Amgen announced positive results from a Phase'3
clinical study of ENBREL in the treatment of moderate-to-severe plaque psoriasis
and is conducting a second Phase'3 clinical study in psoriasis. REMICADE is
sold worldwide by Centocor, Inc., a subsidiary of Johnson'& Johnson, as
a treatment for other indications, including rheumatoid arthritis, and is currently
in a Phase'2 proof of concept study as a potential treatment for psoriasis.
HUMIRA is sold by Abbott Laboratories and is approved to treat rheumatoid arthritis.
Abbott is undertaking clinical trials in psoriasis and psoriatic arthritis.
Company Address: 225 Binney Street Cambridge 2142 MA
Company Phone Number: 679-2000 Stock Exchange / Ticker: NASDAQ BIIB
BIIB is expected to report next financial results on July 19, 2023. |
|
|
|
Customers Net Income grew by |
BIIB's Customers Net Profit Margin fell to |
8.68 % |
4.26 %
|
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Lakeland Industries Inc
Investors, rejoice! The stock market has shown promising growth with Lakeland Industries Inc announcing impressive earnings for the first quarter of 2024. The company's earnings per share have advanced by 28.57% to $0.18 per share compared to $0.14 per share from the previous year, and notably, it has even surpassed its earnings of $0.00 per share from the prior reporting season. Moreover, Lakeland Industries Inc has reported revenue growth by 5.213% from $27.28 million to $28.70 million from the similar reporting season a year before. Though sequentially, revenue fell by -16.901% from $34.54 million, the company has continued to thrive and has reported net profits of $1.320 million, which is a growth of 16.92% from its net earnings of $1.129 million in the first quarter of 2024 a year ago.
|
Agilent Technologies Inc
Agilent Technologies Inc, a Biotechnology and Pharmaceuticals company has released its financial results for the three months ending April 30, 2023. The company's revenue increased by 6.845% to $1.72 billion as compared to $1.61 billion on a year-over-year basis. Meanwhile, the company's profitability showed significant improvement, with profits rising 12.09% to $1.02 from $0.91 in the prior year reporting season. However, there was a decrease in revenue by -2.221% from $1.76 billion in the preceding period, and profits also fell by -14.29% from $1.19 per share. Despite these reductions, earnings rose by 10.22% from net earnings of $274.000 million reported in the second quarter of the 2023 earnings season a year ago.
|
Steris Plc
Steris Plc, a leading biotechnology and pharmaceuticals company, has announced a significant increase in revenue for the most recent fiscal period. The company reported a year-on-year revenue rise of 311.172% to $2.94 billion, which is an impressive figure. However, the company slipped into a net loss of $-0.60. This news is significant and has caused some concern among investors and stakeholders. Compared to the preceding quarter, the income per share fell from $0.56 per share. On the other hand, revenue doubled by a substantial 322.827% from $696.24 million. In the fourth quarter of 2023, Steris Plc posted a net loss of $-90.386 million, as opposed to the net proceeds of $73.623 million recorded in the same quarter a year before. This decline in profits is concerning and indicates a downward trend.
|
Burzynski Research Institute Inc
As a journalist who closely follows the financial performance of various corporations, I find the latest results from Burzynski Research Institute Inc quite intriguing. This small biotech and pharmaceutical firm has reported an operating deficit of $-0.215998 million for the fourth quarter of 2023. While the company has not yet revealed its revenue figures, it is worth comparing these results with the corresponding period from the previous year. In the fourth quarter of 2022, Burzynski Research Institute Inc had already reported an operating deficit of $-0.131272 million. The fact that the shortfall has further expanded to $-0.216 million in the same quarter of 2023 suggests that the company is going through a turbulent period. However, it's important to note that many businesses face such choppy phases while they try to establish prosperous revenue sources.
|
Immunovant Inc
Immunovant Inc, a clinical stage biopharmaceutical company, has reported their financial results for the fiscal period ending March 31, 2023. According to the report, the company generated revenue of $4.098 million, which is a positive sign. However, the company also reported a net loss of $59.432 million for the same period, higher than the previous year's loss of $47.171 million. The net loss per share has worsened from $1.43 in the previous fiscal year to $1.71 in this fiscal year, indicating that the company is facing some financial challenges.
|
Per Share |
Current |
Earnings (TTM) |
21.58 $ |
Revenues (TTM) |
69.59 $
|
Cash Flow (TTM) |
- |
Cash |
14.76 $
|
Book Value |
94.95 $
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
21.58 $
|
Revenues (TTM) |
69.59 $ |
Cash Flow (TTM) |
- |
Cash |
14.76 $
|
Book Value |
94.95 $ |
Dividend (TTM) |
0 $ |
|
|
|
AVONEX |
|
Segment |
|
|
of total Revenue |
TYSABRI |
|
Segment |
|
|
of total Revenue |
PLEGRIDY |
|
Segment |
|
|
of total Revenue |
Other |
|
Segment |
|
|
of total Revenue |
FAMPYRA |
|
Segment |
|
|
of total Revenue |
TECFIDERA |
|
Segment |
|
|
of total Revenue |
ALPROLIX |
|
Segment |
|
|
of total Revenue |
ELOCTATE |
|
Segment |
|
|
of total Revenue |
|
|
|